SG10201809696UA - Processes and intermediates for preparing a medicament - Google Patents
Processes and intermediates for preparing a medicamentInfo
- Publication number
- SG10201809696UA SG10201809696UA SG10201809696UA SG10201809696UA SG10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA
- Authority
- SG
- Singapore
- Prior art keywords
- intermediates
- processes
- medicament
- preparing
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT 5 Disclosed is a process for the preparation of the following compounds: NH2 N N O N R 1 NC NH2 N N R 2a N R 1 R 1a where R 1, R1a and R 2a have the definitions in the description, as well as a process to 10 prepare other intermediates that may be useful to synthesise downstream products, especially compounds that are useful as medicaments, for instance Bruton’s tyrosine kinase (Btk) inhibitors such as ibrutinib. Also disclosed are other processes, other intermediates and compounds per se . 15 [No available fig.]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786842P | 2013-03-15 | 2013-03-15 | |
| EP13159470 | 2013-03-15 | ||
| EP13197813 | 2013-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201809696UA true SG10201809696UA (en) | 2018-11-29 |
Family
ID=51535892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201809696UA SG10201809696UA (en) | 2013-03-15 | 2014-03-11 | Processes and intermediates for preparing a medicament |
| SG11201507595XA SG11201507595XA (en) | 2013-03-15 | 2014-03-11 | Processes and intermediates for preparing a medicament |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507595XA SG11201507595XA (en) | 2013-03-15 | 2014-03-11 | Processes and intermediates for preparing a medicament |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP2970291B1 (en) |
| JP (1) | JP6777398B2 (en) |
| KR (2) | KR102311329B1 (en) |
| CN (2) | CN105026400A (en) |
| AU (2) | AU2014230935A1 (en) |
| BR (1) | BR112015021856A2 (en) |
| CA (1) | CA2901510C (en) |
| DK (1) | DK2970291T3 (en) |
| EA (1) | EA201591685A1 (en) |
| ES (1) | ES2924193T3 (en) |
| HR (1) | HRP20220628T1 (en) |
| HU (1) | HUE058914T2 (en) |
| LT (1) | LT2970291T (en) |
| MX (2) | MX2015012731A (en) |
| MY (1) | MY194905A (en) |
| PE (1) | PE20151652A1 (en) |
| SG (2) | SG10201809696UA (en) |
| SI (1) | SI2970291T1 (en) |
| WO (1) | WO2014139970A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2846652C (en) | 2011-09-02 | 2019-11-05 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
| CN105884747B (en) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | Preparation method for preparing Bruton's Tyrosine Kinase (BTK) kinase inhibitor |
| CN104447761A (en) * | 2014-11-27 | 2015-03-25 | 广东东阳光药业有限公司 | Method for preparing pyrazole derivative |
| EP3248979B1 (en) | 2015-01-21 | 2021-04-14 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Novel inhibitor of flt3 kinase and use thereof |
| CN105481862B (en) * | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | The new inhibitor and application thereof of FLT3 kinases |
| MY187502A (en) * | 2015-02-27 | 2021-09-24 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| LV15201B (en) * | 2015-08-31 | 2017-07-20 | Latvijas Organiskās Sintēzes Institūts | The method for the preparation of ibrutinib intermediate |
| CN106608877B (en) * | 2015-10-21 | 2018-11-13 | 新发药业有限公司 | One kind replacing Buddhist nun's intermediate 4- amino -3- according to Shandong（4- phenoxy groups）The preparation method of phenyl -1H- pyrazolos [3,4-d] pyrimidine |
| JO3793B1 (en) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | Inhibitors of bruton’s tyrosine kinase and methods of their use |
| JO3794B1 (en) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | Polycyclic compounds as inhibitors of bruton's tyrosine kinase |
| WO2018103058A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018145280A1 (en) * | 2017-02-09 | 2018-08-16 | 合肥合源药业有限公司 | Flt3 kinase inhibitor or crystal forms of salt thereof and preparation method therefor |
| CN107383017B (en) * | 2017-07-20 | 2020-01-14 | 河南师范大学 | Efficient preparation method of ibrutinib |
| US20200369611A1 (en) * | 2017-08-01 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Intermediate compounds and methods |
| CN113906011A (en) * | 2019-05-21 | 2022-01-07 | 詹森药业有限公司 | Processes and intermediates for preparing BTK inhibitors |
| CA3135240A1 (en) | 2019-05-21 | 2020-11-26 | Philip James Pye | Processes and intermediates for preparing a btk inhibitor |
| CN113200987A (en) * | 2021-04-29 | 2021-08-03 | 湖南华腾制药有限公司 | Preparation method of ibrutinib |
| CN115322226B (en) * | 2022-08-17 | 2023-08-11 | 厦门大学 | Covalent targeting arsenic inhibitor and preparation method and application thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK3812002A3 (en) * | 1999-09-17 | 2003-09-11 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
| WO2008121742A2 (en) * | 2007-03-28 | 2008-10-09 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| ES2585902T3 (en) * | 2006-09-22 | 2016-10-10 | Pharmacyclics Llc | Bruton tyrosine kinase inhibitors |
| WO2008054827A2 (en) * | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| ES2460019T3 (en) | 2009-03-31 | 2014-05-13 | Boehringer Ingelheim International Gmbh | Derivatives of 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one and its use as PDE9A modulators |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CA2804648C (en) * | 2010-07-09 | 2019-01-22 | The Walter And Eliza Hall Institute Of Medical Research | Protein kinase inhibitors and methods of treatment |
| EP2632898A4 (en) * | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | Heterocyclic tyrosine kinase inhibitors |
| WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| EA201490265A1 (en) * | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | BLUTON TYROSINKINASE INHIBITORS |
| CN104603124B (en) * | 2012-08-10 | 2018-04-17 | 勃林格殷格翰国际有限公司 | Heteroaromatics as bruton's tyrosine kinase (BTK) inhibitor |
| KR101668574B1 (en) * | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | Bruton's tyrosine kinase inhibitors |
| CN103848810A (en) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | Bruton's tyrosine kinases inhibitor |
-
2014
- 2014-03-11 SG SG10201809696UA patent/SG10201809696UA/en unknown
- 2014-03-11 PE PE2015001956A patent/PE20151652A1/en unknown
- 2014-03-11 EA EA201591685A patent/EA201591685A1/en unknown
- 2014-03-11 HU HUE14708885A patent/HUE058914T2/en unknown
- 2014-03-11 DK DK14708885.0T patent/DK2970291T3/en active
- 2014-03-11 CN CN201480015131.5A patent/CN105026400A/en active Pending
- 2014-03-11 EP EP14708885.0A patent/EP2970291B1/en active Active
- 2014-03-11 MX MX2015012731A patent/MX2015012731A/en unknown
- 2014-03-11 JP JP2015562078A patent/JP6777398B2/en active Active
- 2014-03-11 MY MYPI2015002280A patent/MY194905A/en unknown
- 2014-03-11 AU AU2014230935A patent/AU2014230935A1/en not_active Abandoned
- 2014-03-11 KR KR1020157025525A patent/KR102311329B1/en active IP Right Grant
- 2014-03-11 CN CN202011305518.8A patent/CN112608298A/en active Pending
- 2014-03-11 HR HRP20220628TT patent/HRP20220628T1/en unknown
- 2014-03-11 BR BR112015021856A patent/BR112015021856A2/en not_active Application Discontinuation
- 2014-03-11 SI SI201431956T patent/SI2970291T1/en unknown
- 2014-03-11 SG SG11201507595XA patent/SG11201507595XA/en unknown
- 2014-03-11 WO PCT/EP2014/054621 patent/WO2014139970A1/en active Application Filing
- 2014-03-11 LT LTEPPCT/EP2014/054621T patent/LT2970291T/en unknown
- 2014-03-11 ES ES14708885T patent/ES2924193T3/en active Active
- 2014-03-11 KR KR1020217031854A patent/KR102377688B1/en active IP Right Grant
- 2014-03-11 CA CA2901510A patent/CA2901510C/en active Active
-
2015
- 2015-09-14 MX MX2020012596A patent/MX2020012596A/en unknown
-
2018
- 2018-06-08 AU AU2018204086A patent/AU2018204086B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201507595XA (en) | 2015-10-29 |
| AU2018204086A1 (en) | 2018-06-28 |
| SI2970291T1 (en) | 2022-07-29 |
| AU2014230935A1 (en) | 2015-09-03 |
| EP2970291A1 (en) | 2016-01-20 |
| HUE058914T2 (en) | 2022-09-28 |
| BR112015021856A2 (en) | 2017-07-18 |
| KR20150132172A (en) | 2015-11-25 |
| EP2970291B1 (en) | 2022-05-11 |
| KR102377688B1 (en) | 2022-03-22 |
| MY194905A (en) | 2022-12-22 |
| KR20210123429A (en) | 2021-10-13 |
| HRP20220628T1 (en) | 2022-06-24 |
| JP2016510779A (en) | 2016-04-11 |
| EA201591685A1 (en) | 2016-01-29 |
| KR102311329B1 (en) | 2021-10-14 |
| CA2901510A1 (en) | 2014-09-18 |
| JP6777398B2 (en) | 2020-10-28 |
| PE20151652A1 (en) | 2015-11-12 |
| AU2018204086B2 (en) | 2020-03-12 |
| LT2970291T (en) | 2022-06-10 |
| DK2970291T3 (en) | 2022-08-01 |
| ES2924193T3 (en) | 2022-10-05 |
| MX2020012596A (en) | 2021-02-09 |
| CN105026400A (en) | 2015-11-04 |
| MX2015012731A (en) | 2016-02-18 |
| WO2014139970A1 (en) | 2014-09-18 |
| CA2901510C (en) | 2022-11-29 |
| CN112608298A (en) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201809696UA (en) | Processes and intermediates for preparing a medicament | |
| SA515360007B1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors | |
| MX2021007432A (en) | Compounds and compositions for inhibiting the activity of shp2. | |
| TN2014000427A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| PH12016500531A1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MX357305B (en) | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1. | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| EA030383B9 (en) | Bicyclically substituted uracils, processes for preparation thereof, use thereof, medicament and method for treatment using same | |
| MD20150048A2 (en) | Pyrrolotriazinone derivatives as PI3K inhibitors | |
| MX2016000794A (en) | High potency pancreatin pharmaceutical compositions. | |
| PH12016500003A1 (en) | Compounds and compositions as inhibitors of mek | |
| MY175804A (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
| BR112015000443A2 (en) | 3-substituted estra-1,3,5 (10), 16-tetraene derivatives, process for their manufacture, pharmaceutical preparations containing them, as well as their use for the production of medicaments | |
| MX2016000480A (en) | High potency pancreatin pharmaceutical compositions. | |
| WO2017168454A3 (en) | Novel compounds as btk inhibitors | |
| PH12015502000A1 (en) | Processes and intermediates for preparing a medicament | |
| TH172968A (en) | Process and substance for drug preparation | |
| WO2014153113A3 (en) | Processes and intermediates for the preparation of 3 amino-n-cyclopropyl-2 hydroxypropionamide derivatives | |
| TN2014000085A1 (en) | Substituted annellated pyrimidine and the use thereof |